Date: 2013-06-30
Type of information: R&D agreement
Compound: novel lead compounds
Company: UCB (Belgium) the Lieber Institute for Brain Development (LIBD) (USA)
Therapeutic area: CNS diseases - Neurodegenerative diseases
Type agreement: R&D
Action mechanism:
Disease: cognitive impairment
Details: * On June 30, 2013, UCB and the Lieber Institute for Brain Development (LIBD) have entered a strategic collaboration for the discovery of new drug candidates for treating patients suffering from cognitive impairment. UCB and LIBD will jointly generate novel lead compounds and further optimize them starting from chemical compounds provided by both partners. In addition, the specific interdisciplinary structure of LIBD will bring to the collaboration its unique expertise in translating basic research and drug discovery into effective clinical proof of concept.
Financial terms: Financial details of the collaboration were not disclosed.
Latest news:
